Skip to content
1 min left
0% read
7AI logo

7AI

Technology Company
Boston, Massachusetts, USA
Founded 2024
34

7AI is the first agentic security platform that harnesses the speed, swarming capabilities, and power of AI to finally give defenders the advantage over evolving threats.

Share:

7AI: The Agentic Security Platform

7AI is the first agentic security platform that harnesses the speed, swarming capabilities, and power of AI to finally give defenders the advantage over evolving threats. The 7AI Agentic Security Platform makes decisions and acts autonomously to achieve specific cybersecurity goals without human intervention.

Founded by world-renowned cybersecurity experts Lior Div and Yonatan Striem Amit and backed by Greylock Partners, Sequoia Capital, and Spark Capital, 7AI is leading the agentic security revolution. Learn more at 7ai.com.

Frequently Asked Questions About 7AI

7AI is a finance company. 7AI is the first agentic security platform that harnesses the speed, swarming capabilities, and power of AI to finally give defenders the advantage over evolving threats.

7AI is the first agentic security platform that harnesses the speed, swarming capabilities, and power of AI to finally give defenders the advantage over evolving threats. The 7AI Agentic Security Platform makes decisions and acts autonomously to achieve specific cybersecurity goals without human int.

7AI has been operating since 2024. You can verify their legitimacy through their official website and social media presence.

7AI operates in the finance sector of the cryptocurrency industry. Compare 7AI with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using 7AI, research their track record (operating since 2024), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. 7AI is based in Boston, Massachusetts, USA, has been operating since 2024. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

7AI is based in Boston, Massachusetts, USA, North America.

7AI was founded in 2024. The company currently has 34 employees.

7AI Details

7AI Tags

More About 7AI

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m